Elevation Oncology Inc (ELEV) with a beta value of 1.33 appears to be a promising investment opportunity.
On Tuesday, Elevation Oncology Inc (NASDAQ: ELEV) was -2.28% drop from the session before settling in for the closing price of $0.62. A 52-week range